Compare TG Therapeutics Inc (TGTX) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Ultra Short Bond ETF — how do they compare? TG Therapeutics Inc trades at $54.76 (market cap $8.16B), while Vanguard Ultra Short Bond ETF trades at $49.48 (market cap $10.20B). The key difference: Vanguard Ultra Short Bond ETF is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Vanguard Ultra Short Bond ETF for 61 Days on average.
| TGTX | VUSB | |
|---|---|---|
Market Cap | $8.16B | $10.20B |
Volume | 1,735,121 | 2,664,667 |
Sector | Health | Leveraged / Inverse |
52-Week High | $59.06 | $50.03 |
52-Week Low | $26.94 | $49.41 |
Typical Hold Time | 16 Days | 61 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
VUSB trades at $49.48, up 0.08% with minimal daily movement. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock faces resistance at $50 and support at $49. Recent news highlights potential benefits from short-term bond strategies amid Federal Reserve rate uncertainty.
The outlook remains cautious due to bearish technical signals and interest rate sensitivity. Opportunities include dividend stability with recent payouts, but risks involve Fed policy shifts and market volatility. Investors should weigh short-term bond appeal against broader economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
